Please provide your email address to receive an email when new articles are posted on . Significant improvements in clinical remission rates were observed at 12 weeks with risankizumab vs. placebo (20 ...
Please provide your email address to receive an email when new articles are posted on . At the end of induction, 56% of patients treated with subcutaneous guselkumab vs. 21% on placebo achieved ...
Show More From the Queen Silvia Children's Hospital, Sahlgrenska University Hospital, Gothenburg; University of Umeå, Umeå; University Hospital Lund, Lund; University Children's Hospital, Uppsala, ...
Atezolizumab With or Without Radiotherapy for Advanced Squamous Cell Carcinoma of the Penis (The PERICLES Study): A Phase II Trial Homoharringtonine (HHT) is commonly used for the treatment of Chinese ...
"The CareRA2020 trial did not completely solve the unmet need of patients responding insufficiently to conventional initial therapy for early RA, but it provides opportunities to further optimize the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback